167 related articles for article (PubMed ID: 34500854)
1. Iodide Analogs of Arsenoplatins-Potential Drug Candidates for Triple Negative Breast Cancers.
Miodragović Ð; Qiang W; Sattar Waxali Z; Vitnik Ž; Vitnik V; Yang Y; Farrell A; Martin M; Ren J; O'Halloran TV
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500854
[TBL] [Abstract][Full Text] [Related]
2. Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent.
Miodragović Đ; Merlino A; Swindell EP; Bogachkov A; Ahn RW; Abuhadba S; Ferraro G; Marzo T; Mazar AP; Messori L; O'Halloran TV
J Am Chem Soc; 2019 Apr; 141(16):6453-6457. PubMed ID: 30943017
[TBL] [Abstract][Full Text] [Related]
3. On the mechanism of action of arsenoplatins: arsenoplatin-1 binding to a B-DNA dodecamer.
Troisi R; Tito G; Ferraro G; Sica F; Massai L; Geri A; Cirri D; Messori L; Merlino A
Dalton Trans; 2024 Feb; 53(8):3476-3483. PubMed ID: 38270175
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
5. Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity.
Ferraro G; Pratesi A; Cirri D; Imbimbo P; Maria Monti D; Messori L; Merlino A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668605
[TBL] [Abstract][Full Text] [Related]
6. ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.
Zhang Y; Wang L; Gao P; Sun Z; Li N; Lu Y; Shen J; Sun J; Yang Y; Dai H; Cai H
Int J Mol Med; 2018 Nov; 42(5):2343-2352. PubMed ID: 30226569
[TBL] [Abstract][Full Text] [Related]
7. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
[TBL] [Abstract][Full Text] [Related]
8. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Wawruszak A; Luszczki JJ; Kalafut J; Okla K; Halasa M; Rivero-Muller A; Stepulak A
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357442
[TBL] [Abstract][Full Text] [Related]
9. The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct.
Ferraro G; Cirri D; Marzo T; Pratesi A; Messori L; Merlino A
Dalton Trans; 2021 Jan; 50(1):68-71. PubMed ID: 33320144
[TBL] [Abstract][Full Text] [Related]
10. Chloroform Fraction of Methanolic Extract of Seeds of Annona muricata Induce S Phase Arrest and ROS Dependent Caspase Activated Mitochondria-Mediated Apoptosis in Triple-Negative Breast Cancer.
Kariyil BJ; Ayyappan UPT; Gopalakrishnan A; George AJ
Anticancer Agents Med Chem; 2021; 21(10):1250-1265. PubMed ID: 32951586
[TBL] [Abstract][Full Text] [Related]
11. Beyond Cisplatin: Combination Therapy with Arsenic Trioxide.
Miodragović Ð; Swindell EP; Waxali ZS; Bogachkov A; O'Halloran TV
Inorganica Chim Acta; 2019 Oct; 496():. PubMed ID: 32863421
[TBL] [Abstract][Full Text] [Related]
12. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
13. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
Jiang F; Li Y; Si L; Zhang Z; Li Z
Cell Biol Toxicol; 2019 Aug; 35(4):361-371. PubMed ID: 30612216
[TBL] [Abstract][Full Text] [Related]
14. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
15. Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy.
Xin J; Zhang K; Huang J; Luo X; Gong X; Yang Z; Lin H; Shan H; Gao J
Biomater Sci; 2018 Dec; 7(1):262-271. PubMed ID: 30465673
[TBL] [Abstract][Full Text] [Related]
16. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
18. Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
Teraoka S; Muguruma M; Takano N; Miyahara K; Kawate T; Kaise H; Yamada K; Miyazawa K; Ishikawa T
J Surg Res; 2020 Jun; 250():200-208. PubMed ID: 32092597
[TBL] [Abstract][Full Text] [Related]
19. A novel star-shaped trinuclear platinum(II) complex based on a 1,3,5-triazine core displaying potent antiproliferative activity against TNBC by the mitochondrial injury and DNA damage mechanism.
Wu Y; Zhao D; Shang J; Huang W; Chen Z
Dalton Trans; 2022 Jul; 51(29):10930-10942. PubMed ID: 35731536
[TBL] [Abstract][Full Text] [Related]
20. Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells.
Varghese E; Samuel SM; Varghese S; Cheema S; Mamtani R; Büsselberg D
Biomolecules; 2018 Dec; 8(4):. PubMed ID: 30563138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
